Original research article| Volume 81, ISSUE 1, P49-56, January 2010

Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits



      This study investigated the effects of the low-dose combined oral contraceptive (COC) 2.0 mg chlormadinone acetate (CMA)/0.03 mg ethinylestradiol (EE) (Belara��, Balanca��) on cycle-related physical and emotional disorders in women ���25 years of age.

      Study Design

      A prospective, non-interventional, observational study of 3772 women over six cycles was conducted in 303 office-based gynecological centers throughout Germany.


      CMA/EE provided high contraceptive efficacy with a Pearl index of 0 (95% confidence interval=0.00���0.22) and was generally well tolerated, with no statistically significant weight changes during the observation period (p=.147). CMA/EE intake resulted in a statistically significant improvement in cycle-related physical and emotional symptoms, with a 67% overall reduction in sum score for number and intensity of cycle-related symptoms per patient.


      The results of this study in women ���25 years of age support previous findings that 2.0 mg CMA/0.03 mg EE is an effective low-dose COC, with an excellent tolerability profile, with the additional benefits of significantly reducing both cycle-related physical and emotional symptoms (p���.001); women with the respective preexisting symptoms may, therefore, benefit from CMA/EE contraceptive treatment. Further research is warranted.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Society of Consumer Goods Research (Gesellschaft f��r Konsumg��terforschung). Survey on prevalence of depressive mood and other psychical disorders in German women. Dec 2005���Jan 2006. unpublished.

        • Sangthawan M.
        • Taneepanichskul S.
        A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
        Contraception. 2005; 71: 1-7
        • Bock K.
        • Heskamp M.L.
        • Schramm G.
        Influence of chlormadinone acetate on dysmenorrhea and other cycle-related complaints (original in German language).
        Gyne. 2008; 8: 219-225
        • Schramm G.
        • Steffens D.
        Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara��).
        Clin Drug Invest. 2002; 22: 221-231
        • Schramm G.
        • Steffens D.
        A 12-month evaluation of the CMA-containing oral contraceptive Belara��: efficacy, tolerability and anti-androgenic properties.
        Contraception. 2003; 67: 305-312
        • Schramm G.
        • Heckes B.
        Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
        Contraception. 2007; 76: 84-90
        • Zahradnik H.P.
        • Goldberg J.
        • Andreas J.O.
        Efficacy and safety of the new antiandrogenic oral contraceptive Belara��.
        Contraception. 1998; 57: 103-109
        • Worret I.
        • Arp W.
        • Zahradnik H.P.
        • Andreas J.E.
        • Binder N.
        Acne resolution rates: results of a single-blind, randomised, controlled, parallel phase III trial with EE/CMA (Belara��) and EE/LNG (Microgynon��).
        Dermatology. 2001; 203: 38-44
        • Huber J.C.
        • Heskamp M.L.S.
        • Schramm G.A.K.
        Effect of an oral contraceptive with chlormadinone acetate on depressive mood. Analysis of data from four observational studies.
        Clin Drug Invest. 2008; 28: 783-791
        • American College of Obstetricians and Gynecologists (ACOG)
        Premenstrual syndrome.
        American College of Obstetricians and Gynecologists (ACOG), Washington (DC)2000 ([Apr. 9 (ACOG practice bulletin; no. 15) (reaffirmed 2005)])
        • Connolly M.
        Premenstrual syndrome: an update on definitions, diagnosis and management.
        Adv Psychiatr Treat. 2001; 7: 469-477
        • Merki-Feld G.S.
        Cardiovascular risks associated with low-dose combined oral contraceptives.
        Ther Umsch. 2001; 58: 564-569
        • Pearlstein T.B.
        • Bachmann G.A.
        • Zacur H.A.
        • et al.
        Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
        Contraception. 2005; 72: 414-421
        • Yonkers K.A.
        • Brown C.
        • Pearlstein T.B.
        • et al.
        Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
        Obstet Gynecol. 2005; 106: 492-501
        • Mehta A.K.
        • Ticku M.K.
        An update on GABAA receptors.
        Brain Res Rev. 1999; 29: 196-217
        • Zinder O.
        • Dar D.E.
        Neuroactive steroids: their mechanism of action and their function in the stress response.
        Acta Physiol Scand. 1999; 167: 181-188
        • Epperson C.N.
        • Wisner K.L.
        • Yamamoto B.
        Gonadal steroids in the treatment of mood disorders.
        Psychosom Med. 1999; 61: 676-697